Repros Therapeutics Surges 175% On Positive Phase 2 Results
On Thursday shares of Repros Therapeutics (RPRX) jumped after the company reported positive phase 2 results in women with severe menstrual bleeding due to Uterine Fibroids. Uterine Fibroids are noncancerous growths of the Uterus that most typically occur during childbearing years. The clinical study used the company's Proellex (telapristone acetate).
Study participants were separated into three different groups:
- Thirteen women took 6 mg of Proellex
- Fifteen women took 12 mg of Proellex
- Fourteen women took placebo compound
The study met on the primary endpoint, being cessation of menses, which 52% of patients achieved compared to placebo. The 12 mg dose led to a big reduction in menstrual bleeding. The 12 mg arm of Proellex showed a 100% reduction of diary reports in menstrual bleeding, compared to placebo only obtaining a 25.4% reduction. The company is now evaluating these patients over the course of the next 5 months at which time the company can release additional clinical data for this indication.
The company was hit hard last December after the FDA rejected the drug Androxal, a testosterone drug, The FDA cited that it wanted additional clinical data, because the trials that were set up were not adequate to show proper clinical efficacy. Repros has data coming out in June for its Androxal drug treating hypogonadism -- low levels of testosterone. The CEO has made it clear that if the company doesn't meet the mark with this study, then it will put all effort into the Proellex drug.
Disclosure: no position in any stocks mentioned